Literature DB >> 7878767

Immune status of recipients following bone marrow-augmented solid organ transplantation.

A Zeevi1, M Pavlick, S Lombardozzi, R Banas, O Pappo, A S Rao, P Fontes, J Demetris, R Shapiro, F Dodson.   

Abstract

It has been postulated that the resident "passenger" leukocytes of hematolymphoid origin that migrate from whole organ grafts and subsequently establish systemic chimerism are essential for graft acceptance and the induction of donor-specific nonreactivity. This phenomenon was augmented by infusing 3 x 10(8) unmodified donor bone-marrow cells into 40 patients at the time of organ transplantation. Fifteen of the first 18 analyzable patients had sequential immunological evaluation over postoperative intervals of 5 to 17 months, (which included 7 kidney (two with islets), 7 liver (one with islets), and one heart recipient). The evolution of changes was compared with that in 16 kidney and liver nonmarrow controls followed for 4 to 5 months. The generic immune reactivity of peripheral blood mononuclear cells (PBMC) was determined by their proliferative responses to mitogens (PHA, ConA). Alloreactivity was measured by the recipient mixed lymphocyte reaction (MLR) to donor and HLA-mismatched third-party panel cells. Based on all 3 tests, the recipients were classified as donor-specific hyporeactive, intermediate, and responsive; patients who were globally suppressed made up a fourth category. Eight (53%) of the 15 marrow-treated recipients exhibited progressive modulation of donor-specific reactivity (3 hyporeactive and 5 intermediate) while 7 remained antidonor-responsive. In the nonmarrow controls, 2 (12.5%) of the 16 patients showed donor-specific hyporeactivity, 10 (62.5%) were reactive, and 4 (25%) studied during a CMV infection had global suppression of responsiveness to all stimuli.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7878767      PMCID: PMC3005207          DOI: 10.1097/00007890-199502270-00030

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

Review 1.  Cell migration, chimerism, and graft acceptance.

Authors:  T E Starzl; A J Demetris; N Murase; S Ildstad; C Ricordi; M Trucco
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells.

Authors:  G Eiras; Y Shimizu; G A van Seventer; R J Duquesnoy; A Zeevi
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  Acquired donor-specific hyporesponsiveness in long-term kidney allograft recipients.

Authors:  N L Reinsmoen; A Matas; D Kaufman; D Sutherland; J S Najarian; F H Bach
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 4.  Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.

Authors:  T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

5.  A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients.

Authors:  N L Reinsmoen; D Kaufman; A Matas; D E Sutherland; J S Najarian; F H Bach
Journal:  Transplantation       Date:  1990-11       Impact factor: 4.939

6.  Renal transplant patients with steroid withdrawal evaluated longitudinally for their donor--specific cytotoxic T cell reactivity.

Authors:  E Goulmy; K Bittner; E Blokland; J Pool; G Persijn; J J van Rood; H Lange
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

7.  Evidence for suppressor cells and reduced CML induction by the donor in transplant patients.

Authors:  E M Liburd; V Pazderka; T Kovithavongs; J B Dossetor
Journal:  Transplant Proc       Date:  1978-09       Impact factor: 1.066

8.  Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation.

Authors:  P Fontes; A S Rao; A J Demetris; A Zeevi; M Trucco; P Carroll; W Rybka; W A Rudert; C Ricordi; F Dodson
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

9.  Donor-specific decreased primary and secondary cell-mediated immune responses in patients with well functioning grafts.

Authors:  P F Pfeffer; H Hirschberg; E Thorsby
Journal:  Transplant Proc       Date:  1981-09       Impact factor: 1.066

10.  Renal transplant patients monitored by the cell-mediated lympholysis assay. Evaluation of its clinical value.

Authors:  E Goulmy; T Stijnen; A F Groenewoud; G G Persijn; E Blokland; J Pool; L C Paul; J J van Rood
Journal:  Transplantation       Date:  1989-10       Impact factor: 4.939

View more
  10 in total

1.  Hepatic and intestinal transplantation at the University of Pittsburgh.

Authors:  K Abu-Elmagd; J Fung; J Reyes; A Rao; A Jain; G Mazariegos; W Marsh; J Madariaga; I Dvorchik; J Bueno; J Rogers; J McMichael; F Dodson; H Vargus; J Martin; A Slivka; V Balan; R Corry; J Rakela; N Murase; J Demetris; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1998

Review 2.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

3.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

4.  Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients.

Authors:  A S Rao; P Fontes; F Dodson; A Zeevi; M T Rugeles; K Abu-Elmagd; A Aitouche; G Rosner; M Trucco; A J Demetris; W Rybka; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1996-10       Impact factor: 1.066

5.  Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: a 44 month follow-up.

Authors:  A S Rao; P Fontes; A Iyengar; R Shapiro; F Dodson; R Corry; S Pham; M Jordan; A Zeevi; C Rastellini; A Aitouche; F Egidi; H A Gritsch; J Reyes; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

6.  Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation.

Authors:  A Zeevi; M Pavlick; R Banas; C Bentlejewski; K Spichty; A S Rao; P Fontes; A Iyengar; R Shapiro; F Dodson; M Jordan; S Pham; R Keenan; B Griffith; R Corry; F Egidi; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

7.  Effects of donor bone marrow infusion in clinical lung transplantation.

Authors:  S M Pham; A S Rao; A Zeevi; K R McCurry; R J Keenan; J D Vega; R L Kormos; B G Hattler; J J Fung; T E Starzl; B P Griffith
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

8.  A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results.

Authors:  S M Pham; A S Rao; A Zeevi; R L Kormos; K R McCurry; B G Hattler; J J Fung; T E Starzl; B P Griffith
Journal:  J Thorac Cardiovasc Surg       Date:  2000-04       Impact factor: 5.209

9.  Infusion of donor leukocytes to induce tolerance in organ allograft recipients.

Authors:  S K Salgar; R Shapiro; F Dodson; R Corry; K McCurry; A Zeevi; S Pham; K Abu-Elmagd; J Reyes; M Jordan; R Keenan; B Griffith; T Sesky; L Ostrowski; T E Starzl; J J Fung; A S Rao
Journal:  J Leukoc Biol       Date:  1999-08       Impact factor: 4.962

10.  The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients.

Authors:  R Garcia-Morales; M Carreno; J Mathew; K Zucker; R Cirocco; G Ciancio; G Burke; D Roth; D Temple; A Rosen; L Fuller; V Esquenazi; T Karatzas; C Ricordi; A Tzakis; J Miller
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.